---
document_datetime: 2025-11-23 08:06:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/novothirteen.html
document_name: novothirteen.html
version: success
processing_time: 0.135522
conversion_datetime: 2025-12-27 23:19:38.769383
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# NovoThirteen

[RSS](/en/individual-human-medicine.xml/67111)

##### Authorised

This medicine is authorised for use in the European Union

catridecacog

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on NovoThirteen](#news-on)
- [More information on NovoThirteen](#more-information-on-novothirteen-868)
- [More information on NovoThirteen](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

NovoThirteen is a medicine that prevents excessive bleeding in patients with an inherited blood clotting disorder called 'congenital factor XIII A-subunit deficiency'. It is used to prevent bleeding and to treat any episodes of bleeding that occur during preventative treatment.

NovoThirteen contains the active substance catridecacog.

Expand section

Collapse section

## How is NovoThirteen used?

NovoThirteen can only be obtained with a prescription and treatment with the medicine should be started under the supervision of a doctor experienced in treating rare bleeding disorders.

NovoThirteen is given by injection into a vein. For prevention, it is given once a month as long-term treatment. The dose is based on the patient's weight and, sometimes, factor XIII levels in the blood. For treating a bleeding episode during preventative treatment, the patient is given a single dose based on the patient's weight or, to prevent bleeding from minor surgery, on factor XIII levels.

For more information about using NovoThirteen, see the package leaflet or contact your doctor or pharmacist.

## How does NovoThirteen work?

Factor XIII is a protein involved in the blood clotting process. A specific component of factor XIII called the A-subunit strengthens the clot and prevents further bleeding. Patients with congenital factor XIII A-subunit deficiency do not have enough of the A-subunit, or it does not work correctly, which makes them prone to excessive bleeding. The active substance in NovoThirteen, catridecacog, has the same chemical structure as the human factor XIII A-subunit. By providing the factor XIII A-subunit, NovoThirteen helps to prevent bleeding in these patients.

## What benefits of NovoThirteen have been shown in studies?

NovoThirteen was investigated in a main study involving 41 patients above 6 years of age with congenital factor XIII A-subunit deficiency who had been treated in the past with medicines containing factor XIII. On average, each patient treated preventatively with NovoThirteen had about 0.15 bleeding episodes requiring factor XIII treatment per year. This compared with around 2.9 episodes per year for patients treated with another factor XIII medicine, which was given when necessary to control bleeding.

The safety and effectiveness of NovoThirteen in 6 children below 6 years of age was supported by data from a long-term study during which the patients were given NovoThirteen to prevent bleeding. No bleeding episodes occurred in children treated with NovoThirteen.

A further study followed up 30 patients receiving NovoThirteen for prevention. In 6 bleeding episodes resulting from injury and requiring use of a factor XIII medicine, 5 were treated with single doses of NovoThirteen with good results. Bleeding was also kept satisfactorily under control in a patient given single doses of NovoThirteen before two minor surgeries.

## What are the risks associated with NovoThirteen?

The most common side effect with NovoThirteen (which may affect more than 1 in 3 people) is headache. Other common side effects (which may affect up to 1 in 10 people) are leucopenia (low white blood cell counts, including neutrophils which fight infections), pain in the arms and legs, injection site pain, and the presence in the blood of antibodies that attach to factor XIII and of small protein fragments called 'fibrin D-dimer'.

For the full list of side effects and restrictions of NovoThirteen, see the package leaflet.

## Why is NovoThirteen authorised in the EU?

The main study provided satisfactory results on the effectiveness of preventative long-term use of NovoThirteen in congenital factor XIII A-subunit deficiency, since no severe or life-threatening bleedings occurred during treatment. Also, in patients already receiving preventative treatment, single use of NovoThirteen was effective for treating episodes of bleeding. No major side effects were seen with long term use of NovoThirteen.

The European Medicines Agency therefore decided that NovoThirteen's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of NovoThirteen?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoThirteen have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of NovoThirteen are continuously monitored. Side effects reported with NovoThirteen are carefully evaluated and any necessary action taken to protect patients.

## Other information about NovoThirteen

NovoThirteen received a marketing authorisation valid throughout the EU on 3 September 2012.

NovoThirteen : EPAR - Medicine overview

Reference Number: EMA/429977/2020

English (EN) (140.73 KB - PDF)

**First published:** 25/09/2012

**Last updated:** 26/11/2020

[View](/en/documents/overview/novothirteen-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-793)

български (BG) (164.98 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/bg/documents/overview/novothirteen-epar-medicine-overview_bg.pdf)

español (ES) (140.54 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/es/documents/overview/novothirteen-epar-medicine-overview_es.pdf)

čeština (CS) (162.71 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/cs/documents/overview/novothirteen-epar-medicine-overview_cs.pdf)

dansk (DA) (140.03 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/da/documents/overview/novothirteen-epar-medicine-overview_da.pdf)

Deutsch (DE) (143.24 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/de/documents/overview/novothirteen-epar-medicine-overview_de.pdf)

eesti keel (ET) (128.12 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/et/documents/overview/novothirteen-epar-medicine-overview_et.pdf)

ελληνικά (EL) (162.87 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/el/documents/overview/novothirteen-epar-medicine-overview_el.pdf)

français (FR) (141.1 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/fr/documents/overview/novothirteen-epar-medicine-overview_fr.pdf)

hrvatski (HR) (161.56 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/hr/documents/overview/novothirteen-epar-medicine-overview_hr.pdf)

italiano (IT) (139.3 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/it/documents/overview/novothirteen-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (170.13 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/lv/documents/overview/novothirteen-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (162.66 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/lt/documents/overview/novothirteen-epar-medicine-overview_lt.pdf)

magyar (HU) (161.51 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/hu/documents/overview/novothirteen-epar-medicine-overview_hu.pdf)

Malti (MT) (165.91 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/mt/documents/overview/novothirteen-epar-medicine-overview_mt.pdf)

Nederlands (NL) (140.17 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/nl/documents/overview/novothirteen-epar-medicine-overview_nl.pdf)

polski (PL) (164.1 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/pl/documents/overview/novothirteen-epar-medicine-overview_pl.pdf)

português (PT) (141.04 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/pt/documents/overview/novothirteen-epar-medicine-overview_pt.pdf)

română (RO) (161.1 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/ro/documents/overview/novothirteen-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.73 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/sk/documents/overview/novothirteen-epar-medicine-overview_sk.pdf)

slovenščina (SL) (159.11 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/sl/documents/overview/novothirteen-epar-medicine-overview_sl.pdf)

Suomi (FI) (138.66 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/fi/documents/overview/novothirteen-epar-medicine-overview_fi.pdf)

svenska (SV) (139.39 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

26/11/2020

[View](/sv/documents/overview/novothirteen-epar-medicine-overview_sv.pdf)

NovoThirteen : EPAR - Risk-management-plan summary

English (EN) (90.45 KB - PDF)

**First published:** 26/11/2020

**Last updated:** 21/03/2022

[View](/en/documents/rmp-summary/novothirteen-epar-risk-management-plan-summary_en.pdf)

## Product information

NovoThirteen : EPAR - Product Information

English (EN) (1.48 MB - PDF)

**First published:** 25/09/2012

**Last updated:** 21/03/2022

[View](/en/documents/product-information/novothirteen-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-641)

български (BG) (1.58 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/bg/documents/product-information/novothirteen-epar-product-information_bg.pdf)

español (ES) (1.42 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/es/documents/product-information/novothirteen-epar-product-information_es.pdf)

čeština (CS) (1.55 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/cs/documents/product-information/novothirteen-epar-product-information_cs.pdf)

dansk (DA) (1.48 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/da/documents/product-information/novothirteen-epar-product-information_da.pdf)

Deutsch (DE) (1.53 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/de/documents/product-information/novothirteen-epar-product-information_de.pdf)

eesti keel (ET) (1.46 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/et/documents/product-information/novothirteen-epar-product-information_et.pdf)

ελληνικά (EL) (1.61 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/el/documents/product-information/novothirteen-epar-product-information_el.pdf)

français (FR) (1.48 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/fr/documents/product-information/novothirteen-epar-product-information_fr.pdf)

hrvatski (HR) (1.57 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/hr/documents/product-information/novothirteen-epar-product-information_hr.pdf)

íslenska (IS) (1.48 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/is/documents/product-information/novothirteen-epar-product-information_is.pdf)

italiano (IT) (1.49 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/it/documents/product-information/novothirteen-epar-product-information_it.pdf)

latviešu valoda (LV) (1.58 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/lv/documents/product-information/novothirteen-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.44 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/lt/documents/product-information/novothirteen-epar-product-information_lt.pdf)

magyar (HU) (1.58 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/hu/documents/product-information/novothirteen-epar-product-information_hu.pdf)

Malti (MT) (1.66 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/mt/documents/product-information/novothirteen-epar-product-information_mt.pdf)

Nederlands (NL) (1.47 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/nl/documents/product-information/novothirteen-epar-product-information_nl.pdf)

norsk (NO) (1.45 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/no/documents/product-information/novothirteen-epar-product-information_no.pdf)

polski (PL) (1.61 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/pl/documents/product-information/novothirteen-epar-product-information_pl.pdf)

português (PT) (1.51 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/pt/documents/product-information/novothirteen-epar-product-information_pt.pdf)

română (RO) (1.58 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/ro/documents/product-information/novothirteen-epar-product-information_ro.pdf)

slovenčina (SK) (1.58 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/sk/documents/product-information/novothirteen-epar-product-information_sk.pdf)

slovenščina (SL) (1.55 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/sl/documents/product-information/novothirteen-epar-product-information_sl.pdf)

Suomi (FI) (1.47 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/fi/documents/product-information/novothirteen-epar-product-information_fi.pdf)

svenska (SV) (1.48 MB - PDF)

**First published:**

25/09/2012

**Last updated:**

21/03/2022

[View](/sv/documents/product-information/novothirteen-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0026 27/08/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

NovoThirteen : EPAR - All Authorised presentations

English (EN) (20.8 KB - PDF)

**First published:** 25/09/2012

**Last updated:** 25/09/2012

[View](/en/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-113)

български (BG) (51.97 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/bg/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.21 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/es/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.19 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/cs/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (20.89 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/da/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.08 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/de/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.86 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/et/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.96 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/el/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_el.pdf)

français (FR) (20.89 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/fr/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (43.03 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/hr/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (20.83 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/is/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_is.pdf)

italiano (IT) (20.92 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/it/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.67 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/lv/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.81 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/lt/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.71 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/hu/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (52.7 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/mt/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.37 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/nl/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (20.8 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/no/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.4 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/pl/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.17 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/pt/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.66 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/ro/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (48.9 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/sk/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (33.35 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/sl/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.77 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/fi/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.87 KB - PDF)

**First published:**

25/09/2012

**Last updated:**

25/09/2012

[View](/sv/documents/all-authorised-presentations/novothirteen-epar-all-authorised-presentations_sv.pdf)

NovoThirteen : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (218.67 KB - PDF)

**First published:** 05/12/2012

**Last updated:** 05/12/2012

[View](/en/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-17)

български (BG) (274.34 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/bg/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (223.69 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/es/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (244.54 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/cs/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (218.94 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/da/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (219.72 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/de/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (213.39 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/et/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (214.93 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/el/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (213.77 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/fr/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (213.84 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/is/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (213.68 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/it/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (298.76 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/lv/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (240.59 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/lt/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (235.74 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/hu/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (245.23 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/mt/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (213.9 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/nl/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (213.63 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/no/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (243.26 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/pl/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (264.12 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/pt/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (205.14 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/ro/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (236.8 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/sk/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (234.68 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/sl/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (166.15 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/fi/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (213.83 KB - PDF)

**First published:**

05/12/2012

**Last updated:**

05/12/2012

[View](/sv/documents/conditions-member-states/novothirteen-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine NovoThirteen Active substance catridecacog International non-proprietary name (INN) or common name catridecacog Therapeutic area (MeSH) Blood Coagulation Disorders, Inherited Anatomical therapeutic chemical (ATC) code B02BD11

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.

## Authorisation details

EMA product number EMEA/H/C/002284 Marketing authorisation holder

Novo Nordisk A/S

Novo Allé

Opinion adopted 24/05/2012 Marketing authorisation issued 03/09/2012 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

NovoThirteen : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (173.36 KB - PDF)

**First published:** 25/03/2014

**Last updated:** 21/03/2022

[View](/en/documents/procedural-steps-after/novothirteen-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

NovoThirteen-H-C-002284-II-0026-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/539227/2020

English (EN) (765.75 KB - PDF)

**First published:** 21/03/2022

[View](/en/documents/variation-report/novothirteen-h-c-002284-ii-0026-g-epar-assessment-report-variation_en.pdf)

NovoThirteen-H-C-2284/II/0026/G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/539227/2020

English (EN) (765.75 KB - PDF)

**First published:** 26/11/2020

[View](/en/documents/variation-report/novothirteen-h-c-2284ii0026g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for NovoThirteen (II-26-G)

Adopted

Reference Number: EMA/CHMP/385004/2020

English (EN) (131.89 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-novothirteen-ii-26-g_en.pdf)

NovoThirteen-H-C-2284-P46-0016 : EPAR - Assessment Report

Adopted

Reference Number: EMA/18173/2017

English (EN) (429.64 KB - PDF)

**First published:** 12/01/2017

**Last updated:** 12/01/2017

[View](/en/documents/variation-report/novothirteen-h-c-2284-p46-0016-epar-assessment-report_en.pdf)

NovoThirteen-H-C-2284-P46-0014 : EPAR - Assessment Report

Adopted

Reference Number: EMA/226659/2016

English (EN) (196.86 KB - PDF)

**First published:** 15/04/2016

**Last updated:** 15/04/2016

[View](/en/documents/variation-report/novothirteen-h-c-2284-p46-0014-epar-assessment-report_en.pdf)

NovoThirteen-H-C-2284-II-0002 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/71764/2014

English (EN) (767.5 KB - PDF)

**First published:** 25/03/2014

**Last updated:** 25/03/2014

[View](/en/documents/variation-report/novothirteen-h-c-2284-ii-0002-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for NovoThirteen

Adopted

Reference Number: EMA/CHMP/21116/2014

English (EN) (59.5 KB - PDF)

**First published:** 24/01/2014

**Last updated:** 24/01/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-novothirteen_en.pdf)

## Initial marketing authorisation documents

NovoThirteen : EPAR - Public assessment report

Adopted

English (EN) (1.02 MB - PDF)

**First published:** 25/09/2012

**Last updated:** 25/09/2012

[View](/en/documents/assessment-report/novothirteen-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Novothirteen

Adopted

Reference Number: EMA/CHMP/246097/2012

English (EN) (53.55 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-novothirteen_en.pdf)

#### News on NovoThirteen

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

#### More information on NovoThirteen

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu303179) on 12 December 2003. NovoThirteen was withdrawn from the Community register of orphan medicinal products in July 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on NovoThirteen

- [EMEA-000185-PIP01-08-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000185-pip01-08-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/03/2022

## Share this page

[Back to top](#main-content)